Salvage Treatment with Apatinib for Advanced Non-small-cell Lung Cancer

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2017 Apr 4

PMID 28367065

Citations 41

Authors

Zhengbo Song

Xinmin Yu

Guangyuan Lou

Xun Shi

Yiping Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: No definitive chemotherapeutic regimen has been established in patients with non-small-cell lung cancer (NSCLC) who failed second- or third-line treatment. The aim of this study was to evaluate apatinib, a VEGFR-2 inhibitor, in advanced NSCLC as salvage treatment.

Methods: We evaluated the efficacy and toxicity of apatinib in patients with previously treated advanced NSCLC from 2014 to 2015 in Zhejiang Cancer Hospital. Survival analysis was performed by the Kaplan-Meier method.

Results: Forty-two patients were included in the present study. Four patients achieved partial response, and 22 achieved stable disease, representing a response rate of 9.5% and a disease control rate of 61.9%. Median progression-free survival and overall survival were 4.2 and 6.0 months, respectively. The toxicities associated with apatinib were generally acceptable with a total grade 3/4 toxicity of 50%.

Conclusion: Apatinib appears to have some activity against advanced NSCLC when utilized as salvage treatment.

Citing Articles

Tumor cavitation in patients with non-small-cell lung cancer receiving anti-angiogenic therapy with apatinib.

Cai Q, Hu K, Dong S, Li X, Hu S, Deng W Transl Lung Cancer Res. 2024; 13(7):1708-1717.

PMID: 39118887 PMC: 11304154. DOI: 10.21037/tlcr-24-465.

Machine Learning and Health Science Research: Tutorial.

Cho H, She J, De Marchi D, El-Zaatari H, Barnes E, Kahkoska A J Med Internet Res. 2024; 26():e50890.

PMID: 38289657 PMC: 10865203. DOI: 10.2196/50890.

Apatinib successfully administered in malignant tumour patients with severe hypotension: a case series, literature review, and considerations for treatment.

Chen H, Liu X, He M, Gu W, Lu Y J Int Med Res. 2023; 51(6):3000605231177186.

PMID: 37387126 PMC: 10328033. DOI: 10.1177/03000605231177186.

The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial.

Wang J, Huang D, Yang W, Song Q, Jia Y, Chen P Front Oncol. 2022; 12:1030798.

PMID: 36505785 PMC: 9727187. DOI: 10.3389/fonc.2022.1030798.

Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.

Wang W, Shao L, Xu Y, Song Z, Lou G, Zhang Y BMC Pulm Med. 2022; 22(1):179.

PMID: 35524294 PMC: 9074279. DOI: 10.1186/s12890-022-01981-5.

References

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y . Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014; 15(11):1236-44. DOI: 10.1016/S1470-2045(14)70381-X. View

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z . Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014; 135(8):1961-9. DOI: 10.1002/ijc.28829. View

Girard N, Jacoulet P, Gainet M, Elleuch R, Pernet D, Depierre A . Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol. 2009; 4(12):1544-9. DOI: 10.1097/JTO.0b013e3181bbf223. View

Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Goksel T . Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384(9944):665-73. DOI: 10.1016/S0140-6736(14)60845-X. View

Ding J, Chen X, Gao Z, Dai X, Li L, Xie C . Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 2013; 41(6):1195-210. DOI: 10.1124/dmd.112.050310. View

Ghavamipour F, Shahangian S, Sajedi R, Arab S, Mansouri K, Aghamaali M . Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site. FEBS J. 2014; 281(19):4479-94. DOI: 10.1111/febs.12956. View

Song Z, Zhang Y . Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient. J Thorac Dis. 2014; 6(6):856-60. PMC: 4073411. DOI: 10.3978/j.issn.2072-1439.2014.06.15. View

Shepherd F, Dancey J, Ramlau R, Mattson K, Gralla R, ORourke M . Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18(10):2095-103. DOI: 10.1200/JCO.2000.18.10.2095. View

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y . Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34(13):1448-54. DOI: 10.1200/JCO.2015.63.5995. View

10.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

11.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2009; 11(2):121-8. DOI: 10.1016/S1470-2045(09)70364-X. View

12.

Hall R, Le T, Haggstrom D, Gentzler R . Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015; 4(5):515-23. PMC: 4630516. DOI: 10.3978/j.issn.2218-6751.2015.06.09. View

13.

Shaw A, Kim D, Nakagawa K, Seto T, Crino L, Ahn M . Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25):2385-94. DOI: 10.1056/NEJMoa1214886. View

14.

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V . Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27(8):1227-34. DOI: 10.1200/JCO.2007.14.5466. View

15.

Hanrahan E, Heymach J . Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res. 2007; 13(15 Pt 2):s4617-22. DOI: 10.1158/1078-0432.CCR-07-0539. View

16.

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

17.

Aziz M, Serya R, Lasheen D, Abdel-Aziz A, Esmat A, Mansour A . Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents. Sci Rep. 2016; 6:24460. PMC: 4832243. DOI: 10.1038/srep24460. View

18.

Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y . Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013; 31(26):3219-25. DOI: 10.1200/JCO.2013.48.8585. View

19.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

20.

Ding L, Li Q, You K, Jiang Z, Yao H . The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature. Medicine (Baltimore). 2016; 95(20):e3598. PMC: 4902403. DOI: 10.1097/MD.0000000000003598. View